US-based financial services firm Morgan Stanley has led a $15.3m Series E round for US-based NanoString Technologies, a spin out of Seattle-based Institute for Systems Biology.
US-listed investment bank Morgan Stanley has co-led a $15.3m Series E preferred stock round of financing into NanoString Technologies with investment management company Alliance Bernstein. NanoString is a spinoff from the institute for Systems Biology and develops molecular diagnostic products and tools for translational research. There were also investments from return backers Clarus Ventures, Draper…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
